Background: Platelet transfusion is associated with logistical problems with the national storage guidelines of platelets. This results in decreased function in vivo as a result of the platelet storage lesion, and complications such as allergic or hemolytic reactions and thrombosis. We evaluated a new, freshly prepared platelet modified lysate (PML) product designed to be more procoagulant than fresh and stored platelets.
Methods: Fresh platelets were concentrated, sonicated, and centrifuged to produce PML. Samples of both washed and unwashed PML were evaluated for particle size, concentration, and activity, and then tested for clot kinetics and thrombin generation. PML samples were also stored at various temperatures for durations up to 6 months and evaluated for clot kinetics and thrombin generation throughout.
Results: PML showed significantly higher concentration of platelet microparticles, increased procoagulant properties, and increased thrombin generation as compared to fresh and stored platelets. In addition, PML maintained its clot kinetics over a 6-month storage period with variable storage conditions.
Conclusions: The newly proposed PML product is more procoagulant, stable, and has additional potential applications than currently available platelet products. Further studies will be performed to assess its functions in vivo and to assess thrombotic potential.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/trf.15844 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Integrating biomarkers for hemostatic disorders into computational models of blood clot formation: A systematic review.
Math Biosci Eng
December 2024
Laboratory of Optimization, Design, and Advanced Control, School of Chemical Engineering, Universidade Estadual de Campinas, Campinas, São Paulo, Brazil.
In the pursuit of personalized medicine, there is a growing demand for computational models with parameters that are easily obtainable to accelerate the development of potential solutions. Blood tests, owing to their affordability, accessibility, and routine use in healthcare, offer valuable biomarkers for assessing hemostatic balance in thrombotic and bleeding disorders. Incorporating these biomarkers into computational models of blood coagulation is crucial for creating patient-specific models, which allow for the analysis of the influence of these biomarkers on clot formation.
View Article and Find Full Text PDFHow Dendrimers Impact Fibrin Clot Formation, Structure, and Properties.
ACS Omega
December 2024
Department of Biochemistry, Federal University of São Paulo, São Paulo, SP 04044-020, Brazil.
Article Synopsis
- PAMAM dendrimers, known for their structural versatility and customizable surfaces, are being investigated for biomedical uses, but their interactions with blood can disrupt normal clotting and pose health risks.
- The study focused on how low-generation PAMAM dendrimers affect fibrin clot formation dynamics, including clot structure and resistance to breakdown, using various methods and blood samples.
- Notably, certain dendrimers like G2-NH and G4-NH hindered clot formation and altered clot properties significantly, while G3.5-COOH showed minimal impact, suggesting it could be a safer option for medical applications.
Deficiency of neutrophil gelatinase-associated lipocalin elicits Hemophilia-like bleeding and clotting disorder.
Blood
December 2024
School of Basic Medicine, Qingdao University, Qingdao, China.
Coagulation is related to inflammation, but the key pathway, especially innate immune system and coagulation regulation, is not well understood and need to be further explored. Here, we demonstrated that neutrophil gelatinase-associated lipocalin (NGAL), an innate immune inflammatory mediator, is upregulated in thrombosis patients. Furthermore, it contributes to the initiation and amplification of coagulation, hemostasis, and thrombosis.
View Article and Find Full Text PDFWhat, When, and Why: Viscoelastic Hemostatic Assays and Their Uses in Trauma Resuscitation.
Am Surg
December 2024
Department of Surgery, University of Kansas Medical Center, Kansas City, KS, USA.
Viscoelastic hemostatic assays (VHAs) have become a valuable tool in guiding transfusion therapy, particularly in trauma care. While various forms of VHA exist, all provide a quantitative assessment of clot kinetics, strength, and dissolution. Studies have demonstrated that VHA can reduce both mortality and utilization of blood products in the general population.
View Article and Find Full Text PDFDependence of clot structure and fibrinolysis on apixaban and clotting activator.
Res Pract Thromb Haemost
November 2024
Department of Biomedical Engineering, Rutgers University, Piscataway, New Jersey, USA.
Background: Anticoagulants prevent the formation of potentially fatal blood clots. Apixaban is a direct oral anticoagulant that inhibits factor (F)Xa, thereby impeding the conversion of prothrombin into thrombin and the formation of blood clots. Blood clots are held together by fibrin networks that must be broken down (fibrinolysis) to restore blood flow.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!